FDA issued an Early Alert for Abiomed's Automated Impella Controllers due to potential safety concerns following reports of 3 ...

Impella 5.5: A GameChanger for Cardiogenic Shock. Presenter: Jerome Crowley. February 11, 2025. REGISTER for free or LOG IN to view this content. Heart Failure. THT 2025. Hemodynamics. Up Next.

Acute Hemodynamic Effects of Impella 5.5 in Cardiogenic Shock and Decompensated Heart Failure on Hepatorenal Function. Presenter: Gabrielle Daso. February 11, 2025. REGISTER for free or LOG IN to view ...

DANVERS, Mass., March 27, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, the global leader in heart recovery, will feature the latest evidence demonstrating the survival benefit of Impella ...

In Europe, the Impella 2.5, Impella CP and Impella CP with SmartAssist are CE marked for treatment of high-risk PCI and AMI cardiogenic shock patients for up to 5 days. Impella 5.0 and Impella LD ...

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs, researchers demonstrated that 26% experienced worse outcomes ...

Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart ...

Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical ...

Home; Articles; Current Use and Impact of Pulmonary Artery Catheters on the Short-Term Outcomes in Patients With Cardiogenic Shock Treated With an Impella: Findings From the Japan Registry for ...